Loading asset research
Minerva Neurosciences Inc Common Stock
NERVNasdaq · USD · StocksQuote as of · Exchange session not verified$4.15
-0.24%
Today
NERV
Loading 1D prices…
Market cap
$198.2M
Volume
135.9K
52w high
$12.4652w low
$1.93Company profile
Minerva Neurosciences Inc Common Stock
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Burlington, MA, United States
Employees
7
Fiscal year end
1231
CIK
1598646
Session & valuation
Open$4.24
Previous close$4.16
Day high$4.38
Day low$4.13
30-day avg. volume202.8K
Outstanding shares47.7M
Diluted EPS-$34.67
Latest annual period
P/E (trailing)-0.12
P/E (forward)-9.88
Price / book-0.92
Beta-0.10
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ORMPOramed Pharmaceuticals Inc. Common Stock | $193.8M | $2M | +3.77% | $1.50 | -2.10% | Hold |
| KRROKorro Bio Inc. Common Stock | $203.4M | $6.4M | -1834.48% | -$12.48 | +5.74% | Buy |
| TNXPTonix Pharmaceuticals Holding Corp. Common Stock | $203.6M | $13.1M | -946.22% | -$14.57 | -3.34% | Buy |
| DERMJourney Medical Corporation Common Stock | $204.1M | $61.2M | -18.67% | -$0.47 | +2.12% | Buy |
| ANTXAN2 Therapeutics Inc. Common Stock | $204.2M | $0.00 | — | -$1.16 | -4.92% | Buy |